Neurotrope Chief Scientific Officer to Present Keynote Address at Sachs Associates’ 1st Annual …

CEO to Discuss Company’s Disruptive Approach to Alzheimer’s Disease Treatment During Company Presentation NEWARK, N.J., Feb. 23, 2016 (GLOBE NEWSWIRE) — Neurotrope, Inc. ( NTRP ), a clinical-stage company developing a disruptive therapy for the treatment of severe Alzheimer’s disease (AD), today announced that Dr. Daniel Alkon, Neurotrope’s Chief Scientific Officer, is scheduled to present at the Sachs Associates’ 1st Annual Neuroscience Biopartnering & Investment Forum, being held February 23, 2016 at the New York Academy of Sciences in New York City. Dr. Alkon has been invited to be a keynote speaker at the event, along with executives of Pfizer and Axovant Sciences. His presentation titled “New Directions for the Prevention and Reversal of Neurodegeneration” will take place on Tuesday, February 23, 2016 at 10:45 am EST and lead into…


Link to Full Article: Neurotrope Chief Scientific Officer to Present Keynote Address at Sachs Associates’ 1st Annual …